Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.3% over the forecast period (2020-2026). As per the International Diabetes Foundation IDF, around 59.3 million adults in the age range of 20-79 years are living with diabetes in the region in 2019. It represents around 8.9% of the regional population. The rising geriatric population in the region is a major factor for the increasing prevalence of type 2 diabetes in the region. Further, as per the IDF, it is also predicted that the prevalence of diabetes is likely to increase further to 66.0 million in 2030 and which will further reach more than 68.1 million in 2045. Such an increased prevalence of diabetes across the region creates a wide scope for market growth over the forecast period.
To Request a Sample of our Report on Europe Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market: https://www.omrglobal.com/request-sample/europe-dipeptidyl-peptidase-4-inhibitors-market
However, there are severe side effects associated with the use of the dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of lowering blood sugar levels in type 2 diabetic patients. The continuous or long period usage of the dipeptidyl peptidase 4 (DPP-4) inhibitors might lead to headaches, nausea, skin reactions, heart failure, nasopharyngitis, hypersensitivity, and even sometimes cancer. Hence, such aforementioned factors directly impact the growth of the Europe dipeptidyl peptidase 4 (DPP-4) inhibitors industry over the forecast period.
Market Coverage
- Market number available for – 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type
- Regions Covered- Europe
- Competitive Landscape- Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, and Takeda Pharmaceutical Co. among others
(Get 15% Discount on Buying this Report)
A full Report of Europe Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market is Available at: https://www.omrglobal.com/industry-reports/europe-dipeptidyl-peptidase-4-inhibitors-market
Europe Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation
By Type
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Gemigliptin
- Anagliptin
- Teneligliptin
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
